Long-term Consequences of COVID-19: Chemosensory DisordersCOVID-19의 장기적 결과: 화학 감각 장애Review Published on 2023-02-012023-07-11 Journal: Current allergy and asthma reports [Category] COVID19(2023년), [키워드] Gustatory dysfunction Long COVID-19 olfactory dysfunction recovery [DOI] 10.1007/s11882-022-01062-x PMC 바로가기 [Article Type] Review
Lessons from inter-disciplinary collaboration to mitigate SARS-CoV-2 transmission in schools, Ireland, 2020/2021, to inform health systems and multisectoral recoveryarticle Published on 2023-01-162024-09-05 Journal: Frontiers in public health [Category] update2024, [키워드] COVID-19 health systems Interdisciplinary Ireland Multisectoral recovery Resilience Schools [DOI] 10.3389/fpubh.2022.1072566 PMC 바로가기 [Article Type] article
Evaluation of post-COVID health status using the EuroQol-5D-5L scaleObservational Study Published on 2022-12-012023-07-08 Journal: Pathogens and global health [Category] COVID19(2023년), [키워드] COVID-19 EuroQoL long-COVID Post-COVID recovery [DOI] 10.1080/20477724.2022.2035623 PMC 바로가기 [Article Type] Observational Study
COVID-19 in Memes: The Adaptive Response of Societies to the Pandemic?Article Published on 2022-10-102023-07-10 Journal: International Journal of Environmental Research an [Category] COVID19(2023년), [키워드] COVID-19 Entertainment extreme negative emotions healing Health humor mental health recovery Stress the internet. [DOI] 10.3390/ijerph191912969 PMC 바로가기
Symptomatology and imaging findings in early post-Covid period: A comparative study in older vs younger patientsArticle Published on 2022-10-012023-07-10 Journal: Experimental gerontology [Category] COVID19(2023년), [키워드] COVID-19 Follow-up imaging Outpatient recovery Symptom [DOI] 10.1016/j.exger.2022.111907 PMC 바로가기
Multiple deadlocks in the development of nonprofit drugsArticle Published on 2022-09-012022-10-04 Journal: Drug discovery today [Category] 신약개발, [키워드] addressed administer biomedicine Cancer clinical clinical trial clinical trials Community country COVID-19 COVID-19 pandemic Dexamethasone disulfiram drug drugs effort Healthcare system identify Multiple Nonprofit drugs Nonprofit drugs. organized pandemic recovery Research shown [DOI] 10.1016/j.drudis.2022.06.001 PMC 바로가기 [Article Type] Article
Correlation of clinical characteristics between patients with seasonal influenza and patients infected by the wild type or delta variant of SARS-CoV-2Article Published on 2022-08-182022-11-16 Journal: Frontiers in Public Health [Category] SARS, 변종, [키워드] acute respiratory syndrome alleviate Antibiotics antiviral drug bacterial co-infection Biomarker Clinical characteristics Cohort cohorts Comorbidity connection coronavirus correlation COVID-19 COVID-19 cohort COVID-19 pandemic COVID-19 vaccines delta variant demonstrated disease onset flu greater hematological parameters hospital hospital discharge Hospitalization immunization impairment individual Influenza information laboratory data male median age Mild mild cases Myocardial Patient patients with COVID-19 patients with influenza recovery remained renal SARS-CoV-2 Seasonal influenza the patient Treatment variant variant of SARS-CoV-2 viral disease Viremia wild type wild-type with COVID-19 [DOI] 10.3389/fpubh.2022.981233 PMC 바로가기
Should RECOVERY have used response adaptive randomisation? Evidence from a simulation studyRandomized Controlled Trial Published on 2022-08-062022-10-04 Journal: BMC Medical Research Methodology [Category] SARS, 임상, [키워드] adaptive adaptive randomisation Adaptive trial Arm ARMS Care Community coronavirus COVID-19 COVID-19 mortality COVID-19 therapy defined Dexamethasone effective error rate estimate exhibiting FIVE fixed form hospitalised Hydroxychloroquine induce Lopinavir-ritonavir lower mortality Measures mortality rate other diseases Patient patient death patient subgroup performed Platform trial question randomisation randomised controlled trial Randomised Evaluation receiving recovery RECOVERY trial reduced reducing reduction REMAP-CAP representing Respiratory Support Response-adaptive randomization Simulation standard care Statistical power tested Treatment Trial Two-arm [DOI] 10.1186/s12874-022-01691-w PMC 바로가기 [Article Type] Randomized Controlled Trial
T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19심각한 COVID-19 이후 12개월 동안 T 세포 회복 및 지속적인 면역 활성화의 증거Article Published on 2022-08-012022-09-11 Journal: Allergy [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] accompanied acute infection administration analyzed assays Asymptomatic CD38 CD4 CD8 Characteristics clinical recovery coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Critical Cytometry dysregulated immune response enrolled Evidence evidence of exhibited exhibiting expression flow cytometry Follow-up functional hallmark HLA-DR immune activation impairment independent independent of individual Infection investigated lymphopenia Mild Most patients normalization Patient persistent phenotype phenotypic Post-infection pro-inflammatory cytokine proteomics recovery SARS-CoV-2 severe COVID-19 severe COVID-19 patient severe COVID-19 patients subgroup of patient T cell T cells T-cell T-cell activation T-cell Response These cells timepoint viral antigens [DOI] 10.1111/all.15372 PMC 바로가기 [Article Type] Article
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysisCOVID-19로 병원에 입원한 환자의 바리시티닙(RECOVERY): 무작위, 통제, 공개 라벨, 플랫폼 시험 및 업데이트된 메타 분석Meta-Analysis Published on 2022-07-302022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 28-day mortality 95% CI age-adjusted rate ratio allocation Baricitinib benefit by mouth cause Corticosteroid Corticosteroids COVID-19 COVID-19 therapy death deaths died discharge eight enrolled evaluate Evidence hospital hospitalised Including Infection inhibitor Innovation intention-to-treat population ISRCTN Jak JAK inhibitor jak inhibitors janus Janus kinase Medical Research Council Meta-analysis mouth nine Non-COVID-19 once daily Open-label outcomes Patient Platform trial Primary outcome Proportional reduction randomisation randomised randomised controlled trial Randomised Evaluation Randomly randomly assigned patient rate ratio receive receiving recorded recovery RECOVERY trial reduce mortality reduced reduction in mortality Registered risk of death significantly Standard of care suggested thrombosis Tocilizumab Treatment Trial trials usual care usual care alone usual care group was done with COVID-19 [DOI] 10.1016/S0140-6736(22)01109-6 PMC 바로가기 [Article Type] Meta-Analysis